Oxbryta / Voxelotor Withdrawn From Market Due To Serious Health Risks
Sickle Cell Disease Patients May Be Entitled To Compensation
In September 2024, the FDA issued a formal alert to patients, caregivers, and healthcare professionals, recommending the discontinuation of Oxbryta prescriptions. Oxbryta (voxelotor) is a medication manufactured by Pfizer that had been approved to manage sickle cell disease (SCD). However, studies revealed an increased risk of vaso-occlusive crises and mortality in patients who were taking this drug.
Cohen & Malad, LLP is actively investigating legal claims related to Oxbryta injuries. If you or a loved one suffered adverse effects after using Oxbryta, contact our experienced pharmaceutical drug attorney team to learn your rights and options.
Understanding Vaso-Occlusive Crises in Sickle Cell Disease
Sickle cell disease is a genetic disorder that alters red blood cell shape, hindering oxygen flow throughout the body. This condition leads to chronic pain, delayed growth, blood clots, and life-threatening complications. These often impact the lungs (acute chest syndrome), spleen, liver, kidneys, and brain. Patients with SCD face higher risks of infections, joint issues, gallstones, and even silent brain injury, which occurs without noticeable stroke symptoms.
A vaso-occlusive crisis is a painful, potentially life-threatening condition where misshaped red blood cells block blood flow, preventing oxygen from reaching tissues. Symptoms often include moderate to severe pain, frequently occurring in the extremities, chest, and back. Children may experience swelling in their hands and feet.
Patients on Oxbryta were at an increased risk for these crises and were more likely to experience fatal outcomes, making the risks of the drug unacceptable for continued use.
Legal Support for Patients Harmed by Oxbryta
As a patient-focused law firm, Cohen & Malad, LLP is dedicated to seeking justice for individuals impacted by Oxbryta’s adverse effects. Our experienced team of pharmaceutical attorneys is currently reviewing claims from those who experienced vaso-occlusive crises or the loss of a loved one after using Oxbryta.
If you or someone you care about suffered from complications due to Oxbryta, you may be eligible for compensation. Cohen & Malad, LLP offers free consultations to discuss your legal options and potential claims. Our experienced pharmaceutical drug litigation attorneys are here to answer your questions and assist you in pursuing your rights. With a deep commitment to helping clients in drug injury cases, we will guide you through each step of the legal process to help secure the compensation you deserve.
